Last 48 quarters of trend data · Healthcare · Rare Disease Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -51.55 | — | 22.17 | — | — | 76.71 | — | 1.27 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 4.70 | 3.78 | 5.21 | 5.16 | 9.30 | 6.33 | 5.33 | 0.94 | 4.09 | 3.63 | 3.14 | 2.65 | 1.69 | 2.15 | 3.55 | 4.05 | 4.14 | 4.14 | 4.32 | 4.47 | 4.26 |
| — | -40.4% | -2.4% | +451.1% | +127.7% | +74.7% | +69.8% | -64.7% | +141.2% | +68.8% | -11.6% | -34.6% | -59.1% | -48.1% | -17.7% | -9.3% | -2.8% | -12.5% | -32.3% | -36.6% | -50.4% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1957.44 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +23030.0% | |
| P/FCF | — | — | 15.39 | — | — | — | — | 1.27 | — | — | — | 86.79 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | -98.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 35.87 | 33.00 | 10.85 | 21.14 | — | 89.98 | — | 0.85 | — | — | — | 52.77 | 11.08 | — | — | — | — | — | — | — | — |
| — | -63.3% | — | +2395.8% | — | — | — | -98.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 8.35 | 289.59 | 12.25 | 27.83 | — | 133.53 | — | 0.86 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +116.9% | — | +3139.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.9% | 93.4% | 94.5% | 89.7% | 90.1% | 45.1% | 93.6% | 98.9% | 92.4% | 94.5% | 91.7% | 93.0% | 65.4% | 95.2% | 94.0% | 93.6% | 93.5% | 93.5% | 94.2% | 93.2% | 94.4% |
| — | +107.3% | +0.9% | -9.3% | -2.4% | -52.3% | +2.1% | +6.4% | +41.3% | -0.7% | -2.5% | -0.6% | -30.1% | +1.7% | -0.1% | +0.4% | -0.9% | -1.8% | +0.5% | +1.0% | -1.6% | |
| Operating Margin | 49.5% | 7.0% | 41.3% | 16.8% | -49.6% | 1.4% | -19.5% | 82.5% | -76.2% | -27.7% | -21.5% | -21.6% | 1.0% | -60.1% | -98.0% | -53.4% | -119.7% | -33.8% | -55.8% | -58.2% | -51.3% |
| — | +391.1% | +311.4% | -79.6% | +34.9% | +105.2% | +9.3% | +481.4% | -7597.0% | +53.9% | +78.0% | +59.5% | +100.8% | -77.6% | -75.6% | +8.3% | -133.4% | +49.5% | +33.9% | +30.1% | +36.8% | |
| Net Margin | 39.4% | -14.4% | 23.2% | -1.0% | -82.0% | 7.5% | -36.3% | 73.7% | -30.9% | -54.2% | -53.1% | -43.6% | -50.7% | -67.6% | -93.0% | -63.1% | -102.1% | -50.3% | -91.9% | -85.2% | -86.7% |
| — | -291.8% | +163.9% | -101.4% | -165.2% | +113.9% | +31.8% | +269.1% | +39.1% | +19.9% | +42.9% | +30.9% | +50.3% | -34.4% | -1.2% | +26.0% | -17.7% | +47.7% | +9.4% | +21.9% | -38.6% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -269.4% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -1698.7% | |
| ROA | 29.7% | -1.6% | 2.7% | -0.1% | -4.9% | 0.6% | -2.5% | 39.7% | -3.7% | -5.7% | -5.4% | -5.0% | -9.9% | -10.2% | -13.5% | -8.4% | -10.4% | -6.5% | -8.4% | -6.8% | -7.3% |
| — | -365.8% | +211.3% | -100.2% | -31.1% | +110.6% | +54.2% | +899.8% | +62.4% | +44.6% | +60.3% | +40.7% | +5.2% | -58.3% | -59.9% | -23.7% | -43.4% | +1.6% | -48.7% | -13.9% | -114.4% | |
| ROIC | 60.9% | — | — | 7.7% | -11.1% | — | — | — | -20.5% | — | — | — | 0.7% | — | — | -19.4% | -32.7% | -32.2% | -24.9% | -9.4% | -8.3% |
| — | — | — | — | +45.7% | — | — | — | -3104.3% | — | — | — | +102.1% | — | — | -105.8% | -294.4% | -131.8% | -108.7% | +12.0% | +32.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 882.73 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +101094.3% | |
| Debt / EBITDA | 3.02 | 15.17 | 4.22 | 6.45 | — | 29.04 | — | 0.40 | — | — | — | 42.39 | 26.59 | — | — | — | — | — | — | — | — |
| — | -47.8% | — | +1517.0% | — | — | — | -99.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.35 | 3.27 | 3.39 | 2.44 | 2.35 | 2.32 | 3.62 | 3.89 | 2.35 | 2.10 | 2.23 | 2.03 | 2.02 | 1.10 | 1.24 | 1.39 | 1.71 | 1.23 | 1.22 | 1.62 | 1.87 |
| — | +41.1% | -6.2% | -37.3% | -0.1% | +10.5% | +62.6% | +91.3% | +16.3% | +91.1% | +79.9% | +46.5% | +18.3% | -10.8% | +1.1% | -14.4% | -8.9% | -43.3% | -66.6% | -63.7% | -57.8% | |
| Quick Ratio | 2.27 | 3.13 | 3.28 | 2.36 | 2.27 | 2.26 | 3.57 | 3.85 | 2.31 | 2.04 | 2.17 | 1.98 | 1.97 | 1.03 | 1.17 | 1.33 | 1.65 | 1.20 | 1.20 | 1.59 | 1.84 |
| — | +38.6% | -8.1% | -38.8% | -1.9% | +10.6% | +64.0% | +94.5% | +17.3% | +99.0% | +85.7% | +49.2% | +19.1% | -14.3% | -2.3% | -16.5% | -10.2% | -44.1% | -66.8% | -63.9% | -57.9% | |
| Interest Coverage | 5.58 | 0.10 | 3.01 | 0.95 | -1.52 | 0.29 | -1.34 | 28.27 | -1.31 | -1.36 | -0.97 | -1.07 | -2.55 | -4.92 | -7.07 | -3.94 | -6.74 | -5.09 | -5.77 | -4.18 | -5.16 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PTCT stock.
PTC Therapeutics, Inc.'s current P/E is -51.5x. The average P/E over the last 1 quarters is 22.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
PTC Therapeutics, Inc.'s current operating margin is 49.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking PTC Therapeutics, Inc.'s business trajectory between earnings reports.